Research
Dengue Program
Dengue virus (DENV) infection causes a spectrum of illness in humans ranging from mild dengue fever (DF) to potentially lethal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Currently, there are no licensed antiviral therapeutics or vaccines for dengue and treatment of dengue relies entirely on supportive fluid management. Read more…
Malaria Program
Malaria represents one of the major life-threatening infectious diseases in the world, with endemic infection in Africa and Southeast Asia causing nearly one million deaths per year. Plasmodium falciparum is estimated to cause 300-500 million infections each year while the other major human malaria pathogen, P. vivax, is estimated to add an additional 250 million cases. In South and Southeast Asia, P. vivax is the cause of about 50% of all malaria cases. While decades-old drug therapies have played a major role in controlling malaria, the emergence of drug-resistant strains of both P. falciparum and P. vivax is now posing a serious challenge to public health. Read more…
Bacterial Pathogens Program
To complete the full spectrum of infectious diseases, the ID IRG has a major research thrust addressing bacterial pathogens, which represent a major cause of morbidity and mortality globally. The emergence of drug-resistance in virtually every major bacterial pathogen, such as extreme drug-resistant Pseudomonas aeruginosa in Singaporean hospitals and drug resistant strains of Mycobacterium tuberculosis (Mtb) in Southeast Asia and Singapore, is outpacing the development of new antibiotics. Read more…
